BSE filing, NSE: WELCURE. Summary written from the filing by ALFA Finder's alert engine.
Welcure Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹0.18
- Market cap
- ₹22.25 Cr
- Revenue (annual)
- ₹365.5 Cr
- Net profit (annual)
- ₹-5.49 Cr
- P/E (TTM)
- -1.3×Sector 45.9×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Welcure Drugs & Pharmaceuticals Ltd
All →Welcure Drugs & Pharmaceuticals Board Meeting Outcome
Welcure Drugs & Pharmaceuticals approved the closure of its Ahmedabad corporate office. Operations will continue uninterrupted with records transferred to the registered office.
Welcure Drugs & Pharmaceuticals Q4 FY26 Results: Net Loss of ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Ltd reported a net loss of ₹49.9 Cr for Q4 FY26.
- Key figure
- Net loss ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Financial Results
Welcure Drugs and Pharmaceuticals reported annual total income of ₹367.00 Crore for FY26. The Board approved audited results, showing a net annual loss of ₹5.49 Crore.
- Value
- ₹367.0 Cr
Welcure Drugs & Pharmaceuticals Board Meeting Date
Welcure Drugs scheduled a board meeting for May 29, 2026. Directors will consider and approve audited financial results for the 2026 fiscal year.
Welcure Drugs & Pharmaceuticals Debt & Borrowing
Welcure Drugs & Pharmaceuticals Ltd confirmed it does not meet SEBI's 'Large Corporate' criteria for the financial year ended March 31, 2026. Consequently, the company is exempt from mandatory incremental borrowing through debt securities. Its outstanding borrowings as of the reporting date were nil.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs & Pharmaceuticals Ltd submitted its Regulation 74(5) certificate for the quarter and year ended March 31, 2026. The registrar, Skyline Financial Services, confirmed that no physical share certificates were received for dematerialization during this period. This is a routine regulatory disclosure with no impact on business operations.
Other other announcement announcements
All →Sharp Investments Other Announcement
Sharp Investments filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing is a routine Regulation 31 disclosure with no transaction.
True Colors Other Announcement
True Colors filed a Crisil monitoring report on IPO proceeds for the quarter ended September 30, 2026. It confirms no deviation from the prospectus objects.
Indokem Other Announcement
Indokem Limited filed its quarterly shareholding pattern for the period ended 30 September 2026, showing promoter holding and public breakdown. Routine SEBI Regulation 31 disclosure with no transaction or business event.
GP Petroleums Other Announcement
GP Petroleums filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter group holds 37.05% and public shareholders hold 62.95%.
York Exports Other Announcement
York Exports filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing shows promoter and public holdings and beneficial ownership details.
IRM Energy Other Announcement
IRM Energy's Crisil monitoring agency report covers IPO proceeds utilisation for the quarter ended 30 September 2026. The report notes no deviation from the stated objects.